Liso

Idarubicin in combination with intermediate-dose cytarabine and VP-16 in the treatment of refractory or rapidly relapsed patients with acute myeloid leukemia. The GIMEMA Cooperative Group.

L. Pagano, M. Montillo, R. Stasi, 1993, Leukemia.